WO2012085936A3 - Recombinant respiratory syncytial virus plasmids and vaccines - Google Patents

Recombinant respiratory syncytial virus plasmids and vaccines Download PDF

Info

Publication number
WO2012085936A3
WO2012085936A3 PCT/IN2011/000871 IN2011000871W WO2012085936A3 WO 2012085936 A3 WO2012085936 A3 WO 2012085936A3 IN 2011000871 W IN2011000871 W IN 2011000871W WO 2012085936 A3 WO2012085936 A3 WO 2012085936A3
Authority
WO
WIPO (PCT)
Prior art keywords
respiratory syncytial
syncytial virus
vaccines
mva
genes
Prior art date
Application number
PCT/IN2011/000871
Other languages
French (fr)
Other versions
WO2012085936A2 (en
WO2012085936A4 (en
WO2012085936A8 (en
Inventor
Rajesh Jain
Virender Kumar VINAYAK
Neeraj Aggarwal
Pallavi JAISWAL
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of WO2012085936A2 publication Critical patent/WO2012085936A2/en
Publication of WO2012085936A8 publication Critical patent/WO2012085936A8/en
Publication of WO2012085936A3 publication Critical patent/WO2012085936A3/en
Publication of WO2012085936A4 publication Critical patent/WO2012085936A4/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to novel recombinant plasmids comprising a cassette of at least one, or at least two, or at least three or most preferably at least four foreign genes from Respiratory syncytial virus (RSV) wherein the said genes are inserted at a non-essential site preferably Del III, within the modified vaccinia Ankara (MVA) genome. The invention further relates to a recombinant modified vaccinia Ankara (MVA) virus comprising and capable of simultaneous expression of a cassette comprising of at least one, or at least two, or at least three or most preferably at least four foreign genes from Respiratory syncytial virus (RSV), wherein the said genes are inserted at a non-essential site preferably Del III, within the modified vaccinia Ankara (MVA) genome. The invention further provides compositions and method of treatment using the novel recombinant virus.
PCT/IN2011/000871 2010-12-20 2011-12-19 Recombinant respiratory syncytial virus plasmids and vaccines WO2012085936A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3028DE2010 2010-12-20
IN3028/DEL/2010 2010-12-20

Publications (4)

Publication Number Publication Date
WO2012085936A2 WO2012085936A2 (en) 2012-06-28
WO2012085936A8 WO2012085936A8 (en) 2012-08-16
WO2012085936A3 true WO2012085936A3 (en) 2012-10-11
WO2012085936A4 WO2012085936A4 (en) 2012-12-27

Family

ID=45757038

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2011/000871 WO2012085936A2 (en) 2010-12-20 2011-12-19 Recombinant respiratory syncytial virus plasmids and vaccines

Country Status (2)

Country Link
AR (1) AR084439A1 (en)
WO (1) WO2012085936A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7317896B2 (en) 2012-08-01 2023-07-31 バヴァリアン・ノルディック・アクティーゼルスカブ Recombinant modified vaccinia virus Ankara (MVA) respiratory syncytial virus (RSV) vaccine

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014005643A1 (en) * 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
HRP20211756T1 (en) * 2012-07-05 2022-02-18 Glaxosmithkline Biologicals Sa Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
EP3656396A1 (en) * 2012-08-01 2020-05-27 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
JP6664338B2 (en) 2014-06-13 2020-03-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Immunogenic combination

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001004335A2 (en) * 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Department Of Health And Humanservices Human-bovine chimeric respiratory syncytial virus vaccines
WO2010075491A2 (en) * 2008-12-24 2010-07-01 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010250780A1 (en) 2009-05-18 2012-01-12 Panacea Biotec Ltd Universal influenza vaccine based on recombinant modified vaccinia Ankara virus (MVA)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001004335A2 (en) * 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Department Of Health And Humanservices Human-bovine chimeric respiratory syncytial virus vaccines
WO2010075491A2 (en) * 2008-12-24 2010-07-01 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TECHAARPORNKUL S ET AL: "Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 75, no. 15, 1 August 2001 (2001-08-01), pages 6825 - 6834, XP002301669, ISSN: 0022-538X, DOI: 10.1128/JVI.75.15.6825-6834.2001 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7317896B2 (en) 2012-08-01 2023-07-31 バヴァリアン・ノルディック・アクティーゼルスカブ Recombinant modified vaccinia virus Ankara (MVA) respiratory syncytial virus (RSV) vaccine

Also Published As

Publication number Publication date
WO2012085936A2 (en) 2012-06-28
AR084439A1 (en) 2013-05-15
WO2012085936A4 (en) 2012-12-27
WO2012085936A8 (en) 2012-08-16

Similar Documents

Publication Publication Date Title
EP4349405A3 (en) Respiratory virus vaccines
WO2010134094A9 (en) Universal influenza vaccine based on recombinant modified vaccinia ankara virus (mva)
WO2017070620A3 (en) Broad spectrum influenza virus vaccine
PH12018500856A1 (en) Respiratory syncytial virus vaccine
WO2015138357A3 (en) Compositions useful in treatment of otc deficency
HK1205459A1 (en) Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine (mva)(rsv)
DK2579900T3 (en) VECTORS AND SEQUENCES FOR THE TREATMENT OF DISEASES
WO2009065547A3 (en) Poxviral oncolytic vectors
WO2012024621A3 (en) Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus hemagglutinin
MY169352A (en) Vaccine against rsv
WO2012085936A8 (en) Recombinant respiratory syncytial virus plasmids and vaccines
WO2013057570A3 (en) Acrylic polymer formulations
WO2013110818A3 (en) Immunogens for hiv vaccination
WO2009117134A3 (en) Aerosolized genetic vaccines and methods of use
WO2011140595A3 (en) Immunostimulatory and vaccine compositions
WO2009080806A3 (en) Modified influenza virus
MX347587B (en) Asymmetric ureas and medical uses thereof.
WO2012075376A3 (en) Lyophilized viral formulations
WO2013036610A3 (en) Compositions comprising mg53 and methods for the treatment and prevention of airway injury
WO2012154271A3 (en) Method and cells for identifying rig-i pathway regulators
WO2014039966A3 (en) Mouth rinses and tooth sensitivity treatment compositions
WO2014008475A3 (en) Compositions and methods related to viral vaccines
WO2010093537A3 (en) Influenza hemagglutinin and neuraminidase variants
EP2636735A4 (en) Recombinant vaccinia virus having hemagglutinin protein genes derived from novel influenza viruses
WO2011133966A3 (en) Method and compositions for treating ace2-related disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11820848

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11820848

Country of ref document: EP

Kind code of ref document: A2